KYNMOBI市場：市場規模、予測、市場洞察-2032年

KYNMOBIの舌下フィルムは、非エルゴリン・ドパミン作動薬であるアポモルヒネ塩酸塩を含有しています。アポモルヒネ塩酸塩は、白色から光沢のある灰色がかった結晶または白色の粉末で、常温で水およびアルコールにほとんど溶けないです。KYNMOBIは現在、欧州で臨床開発中です。

KYNMOBIの初回投与3日前から、トリメトベンズアミドなどの制吐薬の併用が推奨されます。KYNMOBIの用量範囲は1回10～30mgで、必要に応じて舌下投与します。KYNMOBIの投与は少なくとも2時間間隔をあけるべきです。

KYNMOBIは非エルゴリン型ドパミン作動薬であり、in vitroにおいてドパミンD4受容体に高い親和性を示し、ドパミンD2、D3、D5およびアドレナリン作動性a1D、a2B、a2C受容体には中程度の親和性を示します。

今後数年間で、パーキンソン病の市場シナリオは、世界中の広範な調査と医療費の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、KYNMOBIの優位性に影響を与える可能性のある機会を模索しています。パーキンソン病に対する他の新興製品がKYNMOBIに厳しい市場競争をもたらすと予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるパーキンソン病治療薬のKYNMOBI市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 パーキンソン病におけるKYNMOBIの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 KYNMOBI市場評価

• パーキンソン病におけるKYNMOBI市場の見通し
• 主要7ヶ国分析
  • 主要7ヶ国のパーキンソン病治療におけるKYNMOBI市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: KYNMOBI, Clinical Trial Description, 2023
• Table 2: KYNMOBI, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: KYNMOBI Market Size in the 7MM, in USD million (2019-2032)
• Table 6: KYNMOBI Market Size in the US, in USD million (2019-2032)
• Table 7: KYNMOBI Market Size in Germany, in USD million (2019-2032)
• Table 8: KYNMOBI Market Size in France, in USD million (2019-2032)
• Table 9: KYNMOBI Market Size in Italy, in USD million (2019-2032)
• Table 10: KYNMOBI Market Size in Spain, in USD million (2019-2032)
• Table 11: KYNMOBI Market Size in the UK, in USD million (2019-2032)
• Table 12: KYNMOBI Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: KYNMOBI Market Size in the 7MM, USD million (2019-2032)
• Figure 2: KYNMOBI Market Size in the United States, USD million (2019-2032)
• Figure 3: KYNMOBI Market Size in Germany, USD million (2019-2032)
• Figure 4: KYNMOBI Market Size in France, USD million (2019-2032)
• Figure 5: KYNMOBI Market Size in Italy, USD million (2019-2032)
• Figure 6: KYNMOBI Market Size in Spain, USD million (2019-2032)
• Figure 7: KYNMOBI Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: KYNMOBI Market Size in Japan, USD million (2019-2032)

"KYNMOBI Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about KYNMOBI for Parkinson's disease in the seven major markets. A detailed picture of the KYNMOBI for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the KYNMOBI for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the KYNMOBI market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

KYNMOBI sublingual film contains apomorphine hydrochloride, a nonergoline dopamine agonist. Apomorphine hydrochloride is white to glistening grayish crystals or white powder sparingly soluble in water and alcohol at ambient temperature. KYNMOBI is currently in clinical development in Europe.

Dosage and administration

• For sublingual administration only
• A healthcare provider should supervise dose initiation
• Treatment with a concomitant antiemetic, e.g., trimethobenzamide, is recommended, beginning 3 days before an initial dose of KYNMOBI
• The dose range for KYNMOBI is 10-30 mg per dose, administered sublingually, as needed
• KYNMOBI doses should be separated by at least 2 h
• Maximum of 5 doses per day; maximum single dose is 30 mg

Mechanism of action

KYNMOBI is a nonergoline dopamine agonist with a high in vitro binding affinity for dopamine D4 receptor and moderate affinity for the dopamine D2, D3, and D5, and adrenergic a1D, a2B, a2C receptors.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the KYNMOBI description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on KYNMOBI regulatory milestones and other development activities have been provided in this report.
• The report also highlights the KYNMOBI research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around KYNMOBI.
• The report contains forecasted sales of KYNMOBI for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for KYNMOBI in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KYNMOBI Analytical Perspective by DelveInsight

• In-depth KYNMOBI Market Assessment

This report provides a detailed market assessment of KYNMOBI for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• KYNMOBI Clinical Assessment

The report provides the clinical trials information of KYNMOBI for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KYNMOBI dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to KYNMOBI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KYNMOBI in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of KYNMOBI from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the KYNMOBI in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of KYNMOBI?
• What is the clinical trial status of the study related to KYNMOBI in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KYNMOBI development?
• What are the key designations that have been granted to KYNMOBI for Parkinson's disease?
• What is the forecasted market scenario of KYNMOBI for Parkinson's disease?
• What are the forecasted sales of KYNMOBI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to KYNMOBI for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. KYNMOBI Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. KYNMOBI Market Assessment

• 5.1. Market Outlook of KYNMOBI in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of KYNMOBI in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of KYNMOBI in the United States for Parkinson's disease
  • 5.3.2. Market Size of KYNMOBI in Germany for Parkinson's disease
  • 5.3.3. Market Size of KYNMOBI in France for Parkinson's disease
  • 5.3.4. Market Size of KYNMOBI in Italy for Parkinson's disease
  • 5.3.5. Market Size of KYNMOBI in Spain for Parkinson's disease
  • 5.3.6. Market Size of KYNMOBI in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of KYNMOBI in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options